Clin Osteol 2016; 21(2): 42-48

Osteoporosis in males - a guidelineInformations

J. Rosa. Spolupracovali: J. Blahoą, M. Bayer, P. Broulík, P. Horák, P. Kasalický, I. Kučerová, V. Kuba, ©. Kutílek, V. Palička, R. Pikner, F. ©enk, V. Vyskočil

Published: December 11, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rosa. Spolupracovali: Blahoą JJ, Bayer M, Broulík P, Horák P, Kasalický P, Kučerová I, et al.. Osteoporosis in males - a guideline. Osteologický bulletin. 2016;21(2):42-48.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. NIH consensus development panel on osteoporosis prevention, diagnosis, and t rapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795.
    2. Becker DJ, Kilgore ML, Morrisey MA The societal burden of osteoporosis. Curr Rheumatol Rep 2010;12:186-191. Go to original source...
    3. Rosa J, Palička V, ©enk F. Diagnostika a léčba postmenopauzální osteoporózy. Stanovisko Společnosti pro metabolická onemocnění skeletu ČLS JEP 2015. Osteol Bull 2015;20:150-168.
    4. Cooper C, Melton LJ. Epidemiology of osteoporosis. Trends Endocrinol Metab. 1992;3:224-229. Go to original source...
    5. Bliuc D, Nguyen ND, Milch VE et al. Mortality risk associated with lowosteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301:513-521. Go to original source...
    6. Amin S, Achenbach SJ, Atkinson EJ et al. Trends in fracture in tion-based study over 20 years. J Bone Miner Res.2014;29:581-589. Go to original source...
    7. Cooper C, Cole ZA, Holroyd CR et al. Secular trends in the incidence of hi other osteoporotic fractures. Osteoporos Int 2011;22:1277-1288. Go to original source...
    8. Ústav zdravotních informací a statistiky, 7. 9. 2015, osobní sdělení.
    9. Svedbom A, Hernulund E, Ivergard M et al. Epidemiology and economic burden of osteoporosis in the Czech Republic. A report prepared in collaboration w International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013;8:35-42. Go to original source...
    10. Solomon DH, Johnston SS, Boytsov NN et al. Osteoporosis medication use after hip fractu 1929-1937.
    11. ©těpán J, Vaculík J, Pavelka K et al. Hip Fracture Incidence from 1981 in the Czech Republic as a Basis of the Country-Specific FRAX Model. Calcif Tissue Int 2012;90:365-372. Go to original source...
    12. Seeman E, Bianchi G, Adami S et al. Osteoporosis in Men-Consensus is Premature. Calcif Tissue Int 2004;75:120-122. Go to original source...
    13. Cooper C, Campion G, Melton IJ III. Hip fractures in the elderly: a world projection. Osteoporos Int 1992;2:285-289. Go to original source...
    14. Seeman E, Delmas PD. Bone quality - material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-2261. Go to original source...
    15. Vanderschueren D, Venken K, Ophoff J et al. Sex steroids and the periosteum considering the roles of androgens and estrogens in periostal expansion. J Clin Endocrinol Metab 2006;91:378-382. Go to original source...
    16. Garnero P, Sorney-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal bone loss over 4 years: the OFELY study. J Bone Miner Res 1999;14:1614-21. Go to original source...
    17. Melton LJ III, Khosla S, Achenbach SJ et al. Effects of body size and skeletal teon the estiated prevalence of osteoporosis in women and men. Osteoporos Int 2000;11:977-983. Go to original source...
    18. Aaron JE, Makins NB, Sagreiya K. The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop Relat Res 1987;215:260-71. Go to original source...
    19. Burghardt AJ, Kazakia GJ, RamachandranS LTM, Majumdar S. Age- and genderrelated differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia. J Bone Miner Res 2010;25: 983-993. Go to original source...
    20. Balena R, Shih M-S, Parfitt AM. Bone resorption and formation on the periosteal envelope of the ilium: a histomorphometric study in healthy women. J Bone Miner Res 1992;7:1475-1482. Go to original source...
    21. Bass S, Delmas PD, Pearce G, Hendrich E, Tabensky A, Seeman E. The differing tempo of growth in bone size, mass and density in girls is region-specific. J Clin Invest 1999;104:795-804. Go to original source...
    22. Riggs BL, Melton LJ III, Robb RA et al. A populationbased study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites. J Bone Miner Res 2004;19:1945-1954. Go to original source...
    23. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev 2008;29:441-464. Go to original source...
    24. Drake MT, Khosla S. Male osteoporosis. Endocrinol Metab Clin North Am 2012;41:629-641. Go to original source...
    25. Peacock M, Koller DL, Lai D et al. Bone mineral density variation in men is in­ fluenced by sex-specific and non sex-specific quantitative trait loci. Bone 2009; 45:443-448. Go to original source...
    26. Khosla S, Melton LJ III, Atkinson EJ et al. Relationship of serum sex steroi vels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-2274. Go to original source...
    27. Lapauw B, Taes Y, Goemaere S et al. Anthropometric and skeletal phenotype in men with idiopathic osteoporosis and their sons is consistent with defic gen action during maturation. J Clin Endocrinol Metab 2009;94:4300-4308. Go to original source...
    28. Mellstrom D, Vandenput L, Mallmim H et al. Older men with low serum e and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008;23:1552-1560. Go to original source...
    29. Riggs BL, Melton LJ. Medical progress series: involutional osteoporosis. N J Med 1986;314:1676-1686. Go to original source...
    30. Smith MR Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diab Obes 2007;14:247-254.
    31. ©těpán JJ, Lachman M, Zvěřina J, Pacovský V, Baylink DJ. Castrated men exhi bone loss - effect of calcitonin treatment on biochemical indexes of bone remo­ deling. J Clin Endocrinol Metab 1989;69:523-527. Go to original source...
    32. Stoch SA, Rirker RA, Chen LP et al. Bone loss in men with prostate cancer tr ted with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86:2787-2791. Go to original source...
    33. Shahinian VB, Kuo Y, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-164. Go to original source...
    34. Falahati-Nini A, Riggs BL, Atkinson EJ et al. Relative contributions of t ne and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000;106:1553-1560. Go to original source...
    35. Nielson CM, Marshall LM, Adams AL et al. BMI and fracture ri the osteoporotic fractures in men (MrOS) study. J Bone Miner Res 2010;26:496-502. Go to original source...
    36. Freitas SS, Barrett-Connor E, Ensrud KE et al. Rate and circu vertebral fractures in older men. Osteoporos Int 2008;19:615-623. Go to original source...
    37. Pfeifer M, Sinaki M, Geusens P et al. Musculoske rosis: a review. J Bone Miner Res 2004;19:1208-1214. Go to original source...
    38. Sinaki M, Nwaogwugwu NC, Phillips BE et al. Effect of gender, age, and a pometry on axial and appendicular muscle strength. Am J Phys Med Rehabil 2001;80:330-338. Go to original source...
    39. Hanh M Pham HM, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Contribution of quadriceps weakness to fragility fracture: a prospective study. J Bone Miner 2016;31:208-214. Go to original source...
    40. Watts NB, Adler RA, Bilezikian JP et al. Osteoporosis in Men: An Endocrine Society Clinical Practice. J Clin Endocrinol Metab 2012;97:1802-1822. Go to original source...
    41. Johnell O, Kanis JA, Oden A et al. Predictive Value of BMD for Hip and Other Fractures. J Bone Miner Res 2005;20:1185-1194. Go to original source...
    42. De Laet CEDH, Van Hout BA, Burger H et al. Hip fracture prediction i men and women: validation in the Rotterdam study. J Bone Miner Res 1998; 13:1587-1593. Go to original source...
    43. The European Prospective Osteoporosis Study (EPOS) Group Authors. The rela­ tionship between bone density and i J Bone Miner Res 2002;17:2214-2221. Go to original source...
    44. Watts NB, Leslie WD, Foldes AJ et al. International society for clinical dens metry position development conference: Task Force on Normative Databases. J Clin Densitom 2013;16:472-481. Go to original source...
    45. Schousboe JT, Tanner SB, Leslie WD. Definition of osteoporosis by bone densi­ ty criteria in men: effect of using female instead of male young reference dat pends on skeletal site and densitometer manufacturer. J Clin Densitom 2014;17: 301-306. Go to original source...
    46. Binkley N, Adler R, Bilezikian JP. Osteoporosis Diagnos Controversy Revisited. Curr Osteoporos Rep 2014;12:403-409. Go to original source...
    47. Kanis JA, Bianchi G, Bilezikian JP et al. Towards a diagnostic and therapeu consensus in male osteoporosis. Osteoporos Int 2011;22:2789-2798. Go to original source...
    48. Chubb SAP, Byrnes E, Manning L et al. Reference intervals for bone turnover markers and their association with incident hip fractures in older men: The He In Men study. J Clin Endocrinol Metab 2015;100:90-99. Go to original source...
    49. Luukinen H, Käkonen SM, Pettersson K et al. Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Miner Res 2000;15:2473-2478. Go to original source...
    50. Forsén L, Bjornda A, Bjartveit et al. Interaction Between Current Smoking, Leanness, and Physica Res 1994;9:1671-1678. Go to original source...
    51. Orwoll E, Ettinger M, Weiss S et al. A sis in men. N Engl J Med 2000;343:604-610. Go to original source...
    52. Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established p mary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 2004;24:110-113. Go to original source...
    53. Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int 2009;29:311-315. Go to original source...
    54. Boonen S, Orwoll ES, Wenderoth D et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, place study. J Bone Miner Res 2009;24:719-725. Go to original source...
    55. Orwoll ES, Binkley NC, Lewiecki EM et al. Efficacy and safety of monthly ib dronate in men with low bone density. Bone 2010;46:970-976. Go to original source...
    56. Lyles KW, Colón-Emeric CS, Magaziner JS et al. HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-1809. Go to original source...
    57. Boonen S, Orwoll E, Magaziner J et al. HORIZON Recurrent Fracture Trial. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 2011;59:2084-2090. Go to original source...
    58. Boonen S, Reginster JY, Kaufman JM et al. Fracture risk and rapy in men with osteoporosis. N Engl J Med 2012; 367:1714-1723. Go to original source...
    59. Orwoll ES, Miller PD, Adachi JD et al. Efficacy and safety of a once yearly infusion of zoledronic acid 5 mg versus a once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, ac ve-controlled study. J Bone Miner Res 2010;25:2239-2250. Go to original source...
    60. Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-755. Go to original source...
    61. Orwoll E, Teglbj$rg CS, Langdahl BL et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mine density. J Clin Endocrinol Metab 2012;97:3161-3169. Go to original source...
    62. Cummings SR, San Martin J, McClung MR et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765. Go to original source...
    63. Langdahl BL, Stubbe Teglbj$rg C, Ho P-R et al. A 24-month study evaluating efficacy and safety of denosumab for the treatment of men with low bone mineral density: Results from the ADAMO trial. J Clin Endocrinol Metab 2015;100: 1335-1342. Go to original source...
    64. Recker RR, Marin F, Ish-Shalom S et al. Comparative Effects of Teriparatid Strontium Ranelate on Bone Biopsies and Biochemical Markers ofBone Turnover in Postmenopausal Women With Osteoporosis. J Bone Miner Res 2009;24: 1358-1368. Go to original source...
    65. Quesada-Gómez JM, Muschitz C, Gómez-Reino J et al. The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: Int 2011;22:2529-2537. Go to original source...
    66. Edward T. Middleton ET, Steel SA, Doherty SM. The effect of prior bisphospho­ nate exposure on the treatment response to teriparatide in clinical practice. Cal Tissue Int 2007;81:335-340. Go to original source...
    67. Chavassieux P, Meunier PJ, Roux JP, Portero-Muzy N, Pierre M, Chapurlat R. Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate. J Bone Miner Res 2014;29:618-628. Go to original source...
    68. Kaufman JM, Audran M, Bianchi G et al. Efficacy and safety of strontium rane­ late in the treatment of osteoporosis in men. J Clin Endocrinol Metab 2013;98: 592-601. Go to original source...
    69. Ringe JD, Dorst A, Farahmand P. Efficacy of strontium ranelate on bo density in men with osteoporosis. Arzneimittelforschung 2010;60:267-272. Go to original source...
    70. Orwoll ES, Scheele WH, J^ul S et al. The effect of teriparatide [human pa roid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17. Go to original source...
    71. Kaufman JM, Orwoll E, Goemaere S et al. Teriparatide effects on vertebral fr tures and bone mineral density in men with osteoporosis: treatment and disconti­ nuation of therapy. Osteoporos Int 2005;16:510-516. Go to original source...
    72. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporo­ sis. N Engl J Med 2001;344:1434-1441. Go to original source...
    73. Finkelstein JS, Hayes A, Hunzelman JL et al. The effects of parathyroid hor alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-1226. Go to original source...
    74. Leder BZ, Neer RM, Wyland JJ et al. Effects of teriparatide treatment and continuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 2009;94:2915-2921. Go to original source...
    75. Chen L, Wang G, Zheng F, Zhao H, Li H. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials. Osteoporos Int 2015;26:2355-2363. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.